Continued execution across immuno-neurology platform, with multiple clinical, regulatory and operational milestones achieved in 2019On track to initiate pivotal Phase […]
Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transactionTransaction close anticipated by early […]